Five things for pharma marketers to know: Thursday, July 26, 2018

Share this content:

Biogen and Eisai's Alzheimer's drug demonstrated in a clinical trial that it significantly slowed cognitive decline. Patients receiving the highest dose of BAN2401 performed 30% better than those who received the placebo on a cognitive test. However, only 161 patients were treated with the high dose, and the Phase 2 trial failed its primary goal. (STAT)


Gilead CEO John Milligan is leaving the company at the end of the year. Chairman John Martin also plans to exit when a new chief executive is hired. The company has not named a successor. (Endpoints)


Amgen's new first-in-class migraine treatment is facing difficulties with insurers. Anthem and other insurers have established a set of requirements for patients to qualify for Aimovig, the migraine injection that costs $575 a month. Patients will have to prove they have tried other migraine drugs and document how frequently they suffer a migraine each month, among other requirements. (Reuters)


The health unit at Microsoft is a “multi-billion-dollar business,” according to its chief medical officer. Using its cloud products, the division makes products for 168,000 customers, including hospitals. (CNBC)


Takeda's treatment for lung cancer met its primary endpoint for progression-free survival. The company acquired the non-small-cell lung cancer drug from Ariad and believes it may bring in more than a billion dollars in annual sales. (Endpoints)

Share this content:
Scroll down to see the next article